Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Proceedings

Open Access

Evaluation of effectiveness of protein expression of DNA vaccine in CHO Cells

  • Alexandre Brum1,
  • Andrea Rezende1,
  • Alex Rodrigues1,
  • Henrique Angelo1,
  • Carlos Reis1,
  • Thais Collares2,
  • Claudia Hartleben2,
  • Vasco Azevedo3 and
  • Sibele Borsuk1
BMC Proceedings20148(Suppl 4):P142

https://doi.org/10.1186/1753-6561-8-S4-P142

Published: 1 October 2014

The caseous lymphadenitis (CLA) is a common disease that affects ruminants around the world. The CLA is caused by gram-positive bacteria known as Corynebacterium pseudotuberculosis, which is an intracellular facultative pathogen. In Brazil, the high prevalence occurs principally in northeast and southwest, where has the major herd of sheep and goat causing important economic losses. The actual commercial vaccine confers some level of protection and as based in attenuated or inactive bacteria. The third generation of vaccine includes the DNA vaccine, which can give some advantages as does not cause infection and the stability [13]. Thus the aim of this study was develop and evaluate DNA vaccines based on genes that encode for secreted proteins of C. pseudotuberculosis. For this, we cloned on eukaryotic expression pTARGET vector, gene fragments of C. pseudotuberculosis namely Cp1002_1957 and Cp1002_1802, which encoded for the LipY protein and transferase B protein, respectively. After PCR using specific primers to each gene, the encode sequence were ligated on pTARGET vector (Promega) and the ligation reaction was used to transform Escherichia coli Top10 by eletroporation. The transformation was plated in LB with ampicilin and X-gal substrate. After incubation, the white colonies were select for a screening by digestion with the enzyme EcoRI to confirm gene insertion on vector. Five clones of each gene are selected to transfection of the CHO cells in order to confirm the expression level of proteins by indirect immunofluorescence using sera of mice immunized with the recombinant proteins (rCP1957 and rCP1802). The immunofluorescence analysis show high levels of protein expression (CP1957 and Cp1802) in CHO cells in all clones tested. Both DNA vaccines (pTARGET/1802 and pTARGET/1957) are able to express the proteins in CHO cells in vitro. On the next step, we will perform the animal immunization to confirm the protection level (challenge test) and the immunomodulatory response.

Authors’ Affiliations

(1)
UFPel - biotecnologia - LPDI Laboratório de pesquisa em doenças infecciosas
(2)
UFPel - biotecnologia - Laboratório de imunodiagnóstico
(3)
UFMG - departamento de biologia geral

References

  1. Costa MP, McCulloch JA, Almeida SS, Dorella FA, Fonseca CT, Oliveira DM, Teixeira MF, Laskowska E, Lipinska B, Meyer R, Portela RW, Oliveira SC, MIYOSHI A, Azevedo V: Molecular characterization of the Corynebacterium pseudotuberculosis hsp60-hsp10 operon, and evaluation of the immune response and protective efficacy induced by hsp60 DNA vaccination in mice. BMC Res Notes. 2011, 20 (4): 243-View ArticleGoogle Scholar
  2. Dorella FA, Pacheco LGC, Seyffert N, Portela RW, Meyer R, Miyoshi A, Azevedo V: Antigens of Corynebacterium pseudotuberculosis and prospects for vaccine development. Expert Review of Vaccines. 2009, 8: 205-213. 10.1586/14760584.8.2.205.View ArticlePubMedGoogle Scholar
  3. De Rose R, Ennent J, Mcwaters P, Chaplin PJ: Efficacy of DNA vaccination by different routes of immunization in sheep. Vet Immunol Immunopathol. 2002, 90: 55-63. 10.1016/S0165-2427(02)00221-0.View ArticlePubMedGoogle Scholar

Copyright

© Brum et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement